Literature DB >> 29845207

miRNA expression profiling regulates necroptotic cell death in hepatocellular carcinoma.

Maria Visalli1, Marcello Bartolotta2, Francesca Polito1, Rosaria Oteri1, Adalberto Barbera2, Roberto Arrigo1, Rosa Maria Di Giorgio1, Giuseppe Navarra2, M'hammed Aguennouz1.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer and is among the leading causes of cancer-related mortality worldwide. Although the dysregulation of microRNAs (miRNAs or miRs) has often been reported in HCC, the precise molecular mechanisms by which miRNAs modulate the process of tumorigenesis and the behavior of cancer cells are not yet clearly understood. In this study, we identified a novel three‑miRNA signature, including miR‑371-5p, miR‑373 and miR‑543, that appears to orchestrate programmed cell necrosis in HCC by directly targeting the caspase‑8 gene (Casp‑8). Our results demonstrated that miR‑371-5p, miR‑373 and miR‑543 were overexpressed in HCC tissues compared with paired adjacent normal tissues. The upregulation of these miRNAs specifically and markedly downregulated the expression of Casp‑8, as well as significantly enhanced the Z-VAD/TNF‑α-induced necroptosis of HCC cells. By contrast, the selective knockdown of miRNA expression led to a significant increase in Casp‑8 levels and a marked reduction in programmed cell necrosis. Intriguingly, the sustained overexpression of Casp‑8 reversed the pro‑necroptotic effects exerted by miRNA mimics. Finally, a strong inverse association between the level of miR‑223 and the expression levels of nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing-3 inflammasome was observed in our HCC specimens. On the whole, the present study revealed a molecular link between the three‑miRNA signature, comprising miR‑371-5p, miR‑373 and miR‑543, and the negative necroptotic regulator Casp‑8, and presents evidence for its employment as a novel potential diagnostic, prognostic and therapeutic target in HCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29845207     DOI: 10.3892/ijo.2018.4410

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Multiple roles of microRNA-146a in immune responses and hepatocellular carcinoma.

Authors:  Huihui Wang; Xuemei Li; Tao Li; Lianzi Wang; Xian Wu; Jiaqing Liu; Yuanhong Xu; Wei Wei
Journal:  Oncol Lett       Date:  2019-09-12       Impact factor: 2.967

2.  Inflammasomes and their roles in the pathogenesis of viral hepatitis and their related complications: An updated systematic review.

Authors:  Maryam Dadmanesh; Mohammad Mehdi Ranjbar; Khodayar Ghorban
Journal:  Immunol Lett       Date:  2019-03-01       Impact factor: 3.685

Review 3.  A narrative review of the role of necroptosis in liver disease: a double-edged sword.

Authors:  Xuehui Li; Guanjun Dong; Huabao Xiong; Hongyan Diao
Journal:  Ann Transl Med       Date:  2021-03

4.  Development of a novel necroptosis-associated miRNA risk signature to evaluate the prognosis of colon cancer patients.

Authors:  Yang Huang; Yuanyuan Zou; Qiru Xiong; Chao Zhang; José María Sayagués; Vishal G Shelat; Xingyu Wang
Journal:  Ann Transl Med       Date:  2021-12

5.  Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.

Authors:  Tatyana Masyuk; Anatoliy Masyuk; Christy Trussoni; Brynn Howard; Jingyi Ding; Bing Huang; Nicholas LaRusso
Journal:  JHEP Rep       Date:  2021-08-05

6.  Construction of a Necroptosis-Related miRNA Signature for Predicting the Prognosis of Patients With Hepatocellular Carcinoma.

Authors:  Tongyu Meng; Qingfeng Wang; Yufeng Yang; Yanling Ren; Yan Shi
Journal:  Front Genet       Date:  2022-04-12       Impact factor: 4.772

Review 7.  Non-Coding RNAs and Oral Cancer: Small Molecules With Big Functions.

Authors:  Leila Erfanparast; Mohammad Taghizadieh; Ali Akbar Shekarchi
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.